Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
17.89
+0.07 (0.39%)
At close: Nov 28, 2025, 1:00 PM EST
17.83
-0.06 (-0.34%)
After-hours: Nov 28, 2025, 4:26 PM EST
Company Description
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.
Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer.
The company was founded in 2003 and is headquartered in Miami, Florida.
Summit Therapeutics Inc.
| Country | United States |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 159 |
| CEO | Robert W. Duggan |
Contact Details
Address: 601 Brickell Key Drive, Suite 1000 Miami, Florida 33131 United States | |
| Phone | 305 203 2034 |
| Website | smmttx.com |
Stock Details
| Ticker Symbol | SMMT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001599298 |
| CUSIP Number | 86627T108 |
| ISIN Number | US86627T1088 |
| Employer ID | 37-1979717 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mahkam Zanganeh D.D.S., M.B.A. | Co-Chief Executive Officer, President and Director |
| Robert W. Duggan | Co-Chief Executive Officer and Executive Chairman |
| Manmeet Singh Soni CPA | Chief Operating Officer, Chief Financial Officer and Director |
| Prof. Dame Kay Davies DBE, FRS CBE | Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor |
| Bhaskar Anand | Chief Accounting Officer |
| Nathan LiaBraaten | Senior Director of Investor Relations |
| Dave Gancarz | Chief Business and Strategy Officer |
| Dr. Fong Clow | Chief Biometrics Officer |
| Dr. Urte Gayko Ph.D. | Chief Regulatory, Quality and Pharmacovigilance Officer |
| Dr. Allen S. Yang M.D., Ph.D. | Head of Research & Development Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 7, 2025 | 8-K | Current Report |
| Oct 29, 2025 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Oct 22, 2025 | 8-K | Current Report |
| Oct 20, 2025 | 10-Q | Quarterly Report |
| Oct 20, 2025 | 8-K | Current Report |
| Sep 8, 2025 | 8-K | Current Report |
| Aug 11, 2025 | 8-K | Current Report |
| Aug 11, 2025 | 8-K | Current Report |
| Aug 11, 2025 | 424B5 | Filing |
| Aug 11, 2025 | 10-Q | Quarterly Report |